First Floor | RTx Neighbourhood Our work builds on more than a decade of world leading research conducted by Professor Stuart Forbes and his group at the University of Edinburgh, in partnership with Professor John Campbell at the Scottish National Blood Transfusion Service. Together, the founding team have demonstrated the regenerative potential of macrophages, both in the lab and in the clinic.Our VisionPioneering Regenerative Macrophage Therapy in Inflammatory and Fibrotic DiseasesOur FocusOur initial focus is in end-stage liver disease. It is the only chronic disease still on the rise in western countries, and affects millions of people worldwide. Unfortunately, only supportive therapies are currently available. For patients with end-stage liver disease (cirrhosis) the only therapeutic option is liver transplantation, a complex surgical procedure limited by complications and a shortage of donors. At Resolution, we are developing a macrophage cell therapy product with first-in-class potential to treat patients at risk of hepatic decompensation, with the aim of preventing further decompensations and avoiding the need for a liver transplant. Resolution Therapeutics website Regenerative Macrophage Therapy - a novel solution for inflammatory and fibrotic diseases The Resolutionary corner: a couple of banners and a video will help you understand the workings of Regenerative Macrophage Therapy (RMT), and why it is such a promising revolution in the treatment of inflammatory and fibrotic diseases. If you are interested in some key scientific data supporting our clinical program, you will have an opportunity to see two of our recent conference posters. You will also find some cool mugs and pens that will remind you of the power of RMT once you leave our showcase.Exhibitors: Agata Andruszkow, Gary Shaw, Lara Campana, Anna Hoy, Jose Meseguer, Kayleigh Thirlwell, Alice Johnston, Ross Bunyan Document Usher-Building-Opening-Showcase-02-RtX (1.83 MB / PDF) This article was published on 2025-06-19
